During the recent session, Sangamo Therapeutics Inc (NASDAQ:SGMO)’s traded shares were 3.11 million, with the beta value of the company hitting 1.19. At the last check today, the stock’s price was $2.12, reflecting an intraday gain of 11.01% or $0.21. The 52-week high for the SGMO share is $3.18, that puts it down -50.0 from that peak though still a striking 85.85% gain since the share price plummeted to a 52-week low of $0.30. The company’s market capitalization is $442.40M, and the average intraday trading volume over the past 10 days was 4.29 million shares, and the average trade volume was 7.35 million shares over the past three months.
Sangamo Therapeutics Inc (SGMO) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.88. SGMO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Sangamo Therapeutics Inc (SGMO) registered a 11.01% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 11.01% in intraday trading to $2.12, hitting a weekly high. The stock’s 5-day price performance is 5.49%, and it has moved by -13.10% in 30 days. Based on these gigs, the overall price performance for the year is 384.31%. The short interest in Sangamo Therapeutics Inc (NASDAQ:SGMO) is 14.95 million shares and it means that shorts have 1.7 day(s) to cover.
The consensus price target of analysts on Wall Street is $12, which implies an increase of 82.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $19 respectively. As a result, SGMO is trading at a discount of -796.23% off the target high and -135.85% off the low.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Statistics show that Sangamo Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Sangamo Therapeutics Inc (SGMO) shares have gone up 323.98% during the last six months, with a year-to-date growth rate more than the industry average at 22.03% against 17.10.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -15.96%. While earnings are projected to return 68.33% in 2024.
SGMO Dividends
Sangamo Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Sangamo Therapeutics Inc insiders own 2.36% of total outstanding shares while institutional holders control 27.06%, with the float percentage being 27.71%. WASATCH ADVISORS LP is the largest shareholder of the company, while 129.0 institutions own stock in it. As of 2024-06-30, the company held over 20.09 million shares (or 11.1403% of all shares), a total value of $7.2 million in shares.
The next largest institutional holding, with 14.06 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 7.7963% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.04 million.
Also, the Mutual Funds coming in first place with the largest holdings of Sangamo Therapeutics Inc (SGMO) shares are Wasatch Ultra Growth Fund and Wasatch Microcap Fund. Data provided on Sep 30, 2024 indicates that Wasatch Ultra Growth Fund owns about 10.97 shares. This amounts to just over 5.26 percent of the company’s overall shares, with a $22.39 million market value. The same data shows that the other fund manager holds slightly less at 5.65, or about 2.71% of the stock, which is worth about $11.52 million.
